Tags Posts tagged with "investing"

investing

0 1551

Vitality Biopharma to Present at Biotech Showcase 2017

LOS ANGELES, CA–(Marketwired – Jan 9, 2017) – Vitality Biopharma, Inc. ( OTCQB : VBIO ) (“Vitality Biopharma,” “Vitality,” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will present at the Ninth Annual Biotech Showcase 2017 Conference, on January 11, at the Hilton San Francisco Union Square.

Company CEO Robert Brooke will provide a 30-minute overview of Vitality Biopharma’s business during his presentation and will be available to participate in one-on-one meetings with registered attendees.

Event: Biotech Showcase Conference
Date: Wednesday, January 11, 2017
Time: 8:00 a.m. PT
Track: Room 8 (Ballroom Level)
Location: Hilton San Francisco Union Square, San Francisco, CA

Investors and other interested parties will be able to access a copy of the presentation by visiting the investors section of the Vitality Biopharma website at http://vitality.bio/investors/presentation.

About Biotech Showcase 2017
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences.

About Vitality Biopharma ( OTCQB : VBIO )
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

0 993

 Vitality Biopharma (VBIO) Set To Continue Trend Into “BigWeek” For Biotech?

 

Today’s the day that kicks off JPMorgan’s annual health-care conference; coined the industry’s biggest gathering. As we said last week, many in the space have said that this conference has proven to be a catalyst for the sector overall. So why mention this, as a marijuana focused outlet? Our most recent featured company Vitality Biopharma (VBIO) finds itself at the cross-roads where cannabis meets biotech. Not only did VBIO see a green close on Friday after 3 consecutive days of consolidation but it’s also heading into the week where biotech will seemingly be in the spotlight for many investors.

“Biotech has historically outperformed the broader market during The J.P. Morgan Healthcare Conference,” biotech analysts at the firm wrote in a note to clients ahead of the event.

And we aren’t the only ones who could be seeing the potential “writing on the wall.” One of the presenters at the conference has even said, “…there’s a growing interest in medical cannabis among traditional health care institutions. This is a growing part of what is becoming mainstream health care.” As we said last week, even though we focus specifically on marijuana stocks, the biotech aspect of VBIO could be something to pay attention to heading into this week, considering the historic impact that the JPM conference (starts today) has had in the past for companies that have a stake in the space.


Click Here To View Full VBIO Report


 

Dive Into The Steady Growing Cannabis Market

 

Co-founder of Vapium, a Canadian marijuana vape-maker states, “If you have a passion, any passion, we need advocates and allies. If you’re a baker, we need bakers. If you’re a lawyer, we need lawyers. Anyone who has empathy for people who need weed, and is driven, is welcome in the marijuana industry. There’s still so much opportunity.” The cannabis industry seems like it’s ready to take off. In 2016, the legal weed market in North America Generated $6.7 billion, up 30% from 2015, Arcview Market Research announced.

Washington DC has passed laws allowing…


Click Here To View Full Article


 

Lets Take a Deeper Look at California’s Most Popular Crop

 

California was already known as a major cannabis producer well before it legalized recreational marijuana in November. The state’s marijuana crop is not only the most profitable product in the nation’s biggest agricultural state, it is much farther ahead of the next most popular crop, according to the Orange County Register. California’s mild climate made Central Valley the breadbasket of the world at one time and provided the United States with fruits and vegetables that grew in very few other places. However, the biggest crop in California’s assorted bounty is currently marijuana.


Click Here To View Full Article


Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 2515
marijuana

 

What To Watch With Vitality Biopharma ($VBIO)

 

Vitality Biopharma (VBIO) is staying at the top of our list this week. We’ve witnessed first-hand how strong of a run that this has had and continues to have. Over the last few days we’ve seen VBIO hold a tend above $2.50, where last week it saw a trend in the higher $1 range. In fact since last week, VBIO is trending more than 30% higher than those previous lows. Keep in mind that within the last few weeks VBIO has hit highs of $4.23 so as many of you have already witnessed, this has been capable of dynamic breakouts over shorter periods of time.

This is all happening as the company continues to make progress with their novel therapies. has been going by route of prodrugs. Their unique approach targets CB2 receptors and can be taken orally to directly target specific tissues or organs. Right now, the company is working to create therapies for Crohn’s disease patients and those who suffer from inflammatory bowel disease. VBIO has filed intellectual property applications and is seeking worldwide patent protection through 2035, with strong composition of matter claims for its prodrugs.

In fact, the company’s novel use of certain developmental therapies have been shown to be nearly 10 times as potent as morphine for neuropathic pain relief. And if you remember, they’ve also just received the Drug Enforcement Administration’s approval for its pharma development facility…something that not many of its competitors (if any) can say right now especially in the current climate. Looking for more on VBIO?

 


Click Here To View Full VBIO Report



Things To Expect After Medical Cannabis Is Legal In Florida

Dr. Joseph Dorn was the medical director of Surterra Therapeutics, which is one of six distributing locations that are licensed to dispense medical marijuana in the state of Florida. The constitutional amendment allows higher-strength cannabis to be used for a broader range of medical conditions. However, the true measure of what the amendment means won’t be seen immediately until a new set of rules are carried out by the State’s Legislature.


Click Here To View Full Article


 

#ICYMI: Senator Warren Is Working on Getting Banks To Do Business With The Marijuana Industry

 

As marijuana shops start to sprout and grow within states that have legalized the drug, they face a critical stumbling road block – lack of access to the kind of routine banking services other businesses take for granted. U.S. Sen. Elizabeth Warren, a Massachusetts Democrat, is making a solid attempt at making an effort to ensure vendors working with legal marijuana businesses, from chemists who test marijuana for harmful substances to firms that provide security, don’t have their banking services taken away.

 


Click Here To View Full Article


Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

    7 3278

    We’ve all come here for one reason: Getting Information on Stocks. With most marijuana stocks being considered penny stocks, there are many things that need to be taken into account because yes, they do have higher risk than something like Microsoft or Apple…at least during the early stages of development.

    A lot of the risk comes from volatility in markets. At the drop of a hat a penny stock can explode 20, 50, 100, or even 300% within the matter of weeks or even days. The important part to pay attention to during times of increased volatility is the chart. Historic levels of support and resistance can shed some light on where there are strong points on the chart that show where a price could hold up…especially during times of a pull-back. The main point, as with any stock, is not to let emotion dictate the pace and think logically.

    During times when you get a massive short squeeze and market makers basically need to give up and cover, the second day following a major squeeze needs to be followed closely. Unless there is another monster day of bullish momentum, there’s a good chance that short traders will short even heavier to attempt to make money back after losing “yesterday”. This could trigger some very volatile days to follow and many times, periods of pull-back. The major reason for the pull-back after such a big day has more to do with where the real “retail market” is.

    Obviously a stock can’t go up every day and needs to consolidate but after such a big day on the day of a short squeeze, the market needs to find where the true retail channel is. The point is to stay calm, don’t let emotions dictate the pace. After you see such a big short squeeze, a healthy market will need to find its real base. Keep in mind that most of the time there is a short squeeze, there’s typically more buying coming from short traders and not necessarily retail buying directly. It’s normal to see a pull-back so it’s best to remain calm and pay attention to the historical levels of support and resistance.

    For example if a stock is trading around $2.50-$3.00 consistently and shows clear resistance levels around $3, there’s a good chance that a short is beginning to build in that area. Now say a short squeeze triggers, and that stock has a move above $4; that big move doesn’t necessarily mean that the market is at $4, it could just mean that there wasn’t enough resistance to hold back the price during the time that short sellers needed to buy back shares to cover their short position. Keep in mind that shorting deals with borrowing shares and not borrowing price. What we mean is that if you short a stock, you essentially are borrowing a number of shares of stock and when you need to cover your short, you need to pay back those shares.

    If you were short 100 shares at $2 and now the price is at $4 when you have to cover your short position, you would have been forced to pay double the price in order to pay back your position. This is why we say that a short squeeze doesn’t necessarily represent the true retail market. Again, there can be a lot of volatility following a short squeeze that includes panic selling and heavier shorting so it’s important to stay calm and pay close attention to the trend, sometimes cost averaging at lower prices, or even holding strong as another short squeeze could trigger. All things considered, the final decision is up to you but you should take into account these other factors especially when there is a giant spike in price and volume. A healthy market will not go up every day and taking advantage of the volatility can be where a lot of money could be made.

    0 1667

    In nine states on Tuesday, marijuana legalization measures will appear on the ballot. With this new legalization, investment opportunities are inviting money from Silicon Valley, Wall Street, and publicly traded companies.However, a lot of this new money is avoiding directly investing in marijuana agriculture and sales, which is still illegal under federal law. They are investing in auxiliary products such as grow lights, payroll services, and software.New investors are flocking to get a piece of this market that some people estimate will reach $50 billion throughout the next decade.

    Sports empire scion, Lindy Snider and Silicon Valley angel investor, Fulton Connor are jumping on the bandwagon and investing in software that links growers and retailers. Even Scotts Miracle-Gro, a gardening product manufacturer, knows this industry is about to get big. The company has spent millions of dollars acquiring other companies that sell lighting, soil, fertilizer, and other various products to marijuana growers. Scotts’ chairman and CEO Jim Hagedorn told Forbes that marijuana was “the biggest thing I’ve ever seen in lawn and garden.”

    Microsoft Corp is getting its feet wet in the industry by partnering with Kind Financial to develop software to allow government regulators to follow marijuana from farm to market. Investors believe if California legalizes recreational marijuana use, “…it would triple the size of the legal market,” said financial services firm Cowen and Company analyst Vivien Azer.

    Many Wall Street firms have also started to get involved and guide their clients on how to do well in this market. Merrill Lynch and Cowen have released reports on opportunities to help provide advice to their clients. However, to fully realize the potential of marijuana, federal law needs to be aligned with state legalization laws. People are going crazy to get in to the market before it blows up and they plan on making a lot of profit of their endeavors

    0 1874

    Hemp, I’d like you to meet Marijuana. She’s going to introduce you to her friend, Cannabis Investor, who will show you life in the fast lane…

    For the past century, hemp has been minding its own business, quietly supplying the world with relatively mundane products like rope, textiles, protein, and vegetable oil. Now, with the wave of medical and recreational marijuana legalization that’s sweeping America, that is changing. Legal cannabis has become the fastest growing market in America. And hemp is now coming along for the wild ride.

    The boom in medical and recreational marijuana has been a big attraction to investors, while at the same time being a serious turnoff for investors and entrepreneurs who don’t want to be involved in the drama and legalities surrounding marijuana. But, with all the attention that medical marijuana is enjoying, it’s becoming clear that many of the medicinal benefits of cannabis can be had without the buzz and the legal worries. Enter cannabidiol (CBD), a cannabinoid extracted from agricultural hemp rather than marijuana.

    Hemp CBD is suddenly getting serious attention from health food entrepreneurs who would never consider investing in marijuana. One such entrepreneur is, Tapio Maki who is the founder of Smart Salt, a reduced sodium mineral salt used in processed foods. Maki’s latest venture, CBD Incorporated, was founded specifically to produce CBD from hemp. The new company is currently raising capital to build a mass production facility in Portugal.

    I sat with Tapio to talk about CBD’s attraction as an alternative investment to medical marijuana. Here’s what he had to say.

    I know you’re dead set against investing in either medical or recreational marijuana. What got you interested in investing in CBD?

    Maki: I follow health food industry news. I kept seeing reports about the medical marijuana “Green Rush.” I didn’t give it much consideration because I don’t want to get involved in the legalities and controversy of marijuana. But then I started to notice reports about CBD, which has many of the same benefits of THC but without the high. CBD can actually be extracted more efficiently from agricultural hemp than from marijuana. After doing some more research, I realized that CBD is in a period of exponential growth that will not slow down any time soon. I believe it’s a better investment than marijuana.

    What were the pros and cons for you of getting into the hemp business?

    The “pros” to me are that I’m certain that the sales of CBD products are going to explode in the coming years. The vast majority of people who are into alternative, natural cures don’t want to be high all the time. I did some math based on industry projections and saw that by 2020, the total global cannabis market – hemp and marijuana-related products – could exceed 100 billion dollars. And, although the vast majority of that is currently for marijuana-based products, interest in CBD’s medical benefits is spreading so quickly that the CBD market is going to become a much more substantial percentage of the cannabis market than it is today.

    The cons are that some investors see the word “cannabis” or they see a pot leaf and they think, “oh, marijuana,” and don’t want to get involved. Even the media keeps lumping hemp CBD into medical marijuana because that’s the hot story. But hemp CBD has nothing to do with marijuana and getting high, and everything to do with health.

    You had originally planned to buy and sell CBD rather than producing it. What changed your mind to consider mass production? And why Portugal?

    After leaving my full time position with Smart Salt, I spent a few years sailing, all the time following the market news. I made made landfall in Portugal in 2013 with plans to continue around the Mediterranean. While I was in Portugal I started talking to my European business associates about CBD and hemp. As it turns out, Portugal is an ideal place to grow hemp. It has a climate very similar to California, abundant sunshine and rain, affordable and highly productive farm land. And CBD extraction is legal. It also turns out that you can’t sell CBD nationwide in the US if it’s not imported. Production became a viable option if we set up shop in Portugal and import to the US.

    Your company is investing heavily in extraction technology. How did you come to the decision to develop your own technology to produce CBD rather than using existing technology?

    For one thing, we plan to produce a very high volume of organic CBD and want environmentally friendly technology that’s tailored to our operation. More importantly, we also plan to be a top name in high volume extraction technology and license our technology to other growers as a major source of revenue. We call our product the ‘Liquid Gold Factory.’ A valuable side benefit is that if the price of CBD starts to go down – which will only happen if more and more companies start producing CBD – we’ll be making up the difference by selling more technology.
    ———

    As part of their fundraising efforts, CBD Inc. is offering CBD resellers a lifetime supply of CBD. Pre-order up to 4 kilos of CBD and get the same amount every year, forever. For more info go to http://www.cbdincorporated.com/get-lifetime-supply-cbd/

    Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

    We are your #1 source for all things Marijuana Stocks, Subscribe Below!

    Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
    Ad Placements